Xolair: A Powerful Treatment for Allergic Asthma and Chronic Idiopathic Urticaria Xolair is a medication that has been used successfully in the treatment of respiratory conditions such as allergic asthma and skin conditions such as chronic idiopathic urticaria for over a decade. Xolair is the brand name for omalizumab, that is made from monoclonal antibodies that target IgE, which is an allergic antibody. As in the case with any medication, it is important to understand how it works, how it should be administered, and what side effects one should be aware of. Uses of Xolair Xolair was approved by the FDA in 2003 for the treatment of asthma in patients aged 12 years and older whose asthma is inadequately controlled with inhaled corticosteroids. This type of asthma is also known as allergic asthma. Specifically, it is approved for the treatment of moderate-to-severe persistent asthma in patients who have a positive skin test or in vitro reactivity to a perennial allergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Recently, the FDA also approved Xolair for the treatment of chronic idiopathic urticaria, which is a skin condition that causes hives. Dosage of Xolair Xolair is typically administered every two to four weeks as an injection under the skin by a healthcare provider. The dosage of Xolair depends on the weight and age of the patient, as well as the frequency of administration. For adult patients with moderate-to-severe persistent asthma, the recommended dose of Xolair is 150-375 mg injected subcutaneously every two or four weeks. For patients with chronic idiopathic urticaria, the recommended dose of Xolair is 300 mg injected subcutaneously every four weeks. Demographic Xolair is approved for use in patients aged 12 years and older with allergic asthma. The exact demographic that is a suitable candidate for Xolair depends on the severity and type of asthma. If a person experiences moderate-to-severe asthma that is inadequately controlled with inhaled corticosteroids, they are likely a suitable candidate for Xolair. Additionally, Xolair is approved for patients with chronic idiopathic urticaria. Side Effects The most common side effects of Xolair reported in clinical trials include injection site reactions such as redness, swelling, and itching, headache, viral infections, respiratory tract infections, cough, joint pain, and back pain. Although rare, Xolair can occasionally cause serious side effects such as anaphylaxis, which is life-threatening allergic reactions related to its mechanism of IgE reduction. Not all patients who receive Xolair will experience side effects, and the risk of side effects can be reduced with proper administration and monitoring. Interactions There are currently no known drug interactions between Xolair and other medications, but it is essential to tell your healthcare provider about all medications you are currently taking. It is also important to let your healthcare provider know about any allergies or sensitivities you have had to medications in the past. Generic Options Xolair is a branded medication with no approved generic option available in the United States. It may be available as a biosimilar, which is similar in function and dosage to the original product. Healthcare providers may choose to use biosimilars when available for equivalent efficacy as well as cost savings to healthcare systems. Conclusion Xolair is a powerful medication that has been successful in treating moderate-to-severe asthma and chronic idiopathic urticaria. As with any medication, it is important to understand the risks and benefits of Xolair before it is administered. Talk to your healthcare provider about any questions or concerns about Xolair, and make sure to report any side effects you experience. With proper use and sufficient monitoring, Xolair can improve outcomes for patients who suffer from allergic asthma and chronic idiopathic urticaria.